Literature DB >> 36205826

Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia.

Christoph Weinfurtner1, Klaus Geissler2,3.   

Abstract

In a retrospective study, we analyzed the prevalence of subnormal prothrombin time (PT) values in 104 patients with chronic myelomonocytic leukemia (CMML), their potential prognostic impact, and potential correlations with clinicolaboratory features. Reduced PT values (< 70%) were found in 45/104 (43%) patients. The median survival of patients with reduced PT values was significantly shorter than in patients with normal PT (19 vs. 49 months, p = 0.006). Patients with reduced PT had higher leukocyte counts, a higher proportion of circulating blast cells, and lower platelet counts. In patients for whom clinical information was available, there was no difference in the incidence of bleeding complications between patients with or without reduced PT. Our results show a high prevalence of plasmatic coagulation abnormalities in patients with CMML, which were associated with laboratory features of advanced disease. Moreover, subnormal PT values were identified as a new prognostic marker. Reduced PT values do not seem to have a clinical impact regarding bleeding complications.
© 2022. The Author(s).

Entities:  

Keywords:  Chronic myelomonocytic leukemia; Coagulation; Prevalence; Prothrombin time; Survival

Year:  2022        PMID: 36205826     DOI: 10.1007/s10354-022-00969-4

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  2 in total

1.  Chronic myelomonocytic leukemia.

Authors:  A M Storniolo; W C Moloney; D S Rosenthal; C Cox; J M Bennett
Journal:  Leukemia       Date:  1990-11       Impact factor: 11.528

2.  Real-world Data for Clinical Evidence Generation in Oncology.

Authors:  Sean Khozin; Gideon M Blumenthal; Richard Pazdur
Journal:  J Natl Cancer Inst       Date:  2017-11-01       Impact factor: 13.506

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.